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Abstract
Cancers exhibit abnormal molecular signatures associated with disease initiation
and progression. Molecular signatures could improve cancer screening, detection,
drug development and selection of appropriate drug therapies for individual
patients. Typically only very small amounts of tissue are available from patients for
analysis and biopsy samples exhibit broad heterogeneity that cannot be captured
using a single marker. This report details application of an in-house custom
designed GenomeLab System multiplex gene expression assay, the
hCellMarkerPlex, to assess predictive gene signatures of normal, adenomatous
polyp and carcinoma colon tissue using archived tissue bank material. The
hCellMarkerPlex incorporates twenty-one gene markers: epithelial (EZR, KRT18,
NOX1, SLC9A2), proliferation (PCNA, CCND1, MS4A12), differentiation
(B4GANLT2, CDX1, CDX2), apoptotic (CASP3, NOX1, NTN1), fibroblast (FSP1,
COL1A1), structural (ACTG2, CNN1, DES), gene transcription (HDAC1), stem cell
(LGR5), endothelial (VWF) and mucin production (MUC2). Gene signatures
distinguished normal, adenomatous polyp and carcinoma. Individual gene targets
significantly contributing to molecular tissue types, classifier genes, were further
characterised using real-time PCR, in-situ hybridisation and immunohistochemistry
revealing aberrant epithelial expression of MS4A12, LGR5 CDX2, NOX1 and
SLC9A2 prior to development of carcinoma. Identified gene signatures identify
aberrant epithelial expression of genes prior to cancer development using in-house
custom designed gene expression multiplex assays. This approach may be used to
assist in objective classification of disease initiation, staging, progression and
therapeutic responses using biopsy material.
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Introduction
Colorectal cancer is the fourth most common cause of death from cancer,
accounting for 8% of all cancer deaths [1]. The majority of colorectal cancers arise
from adenomatous polyps. With the advent of population screening large
numbers of asymptomatic individuals are being shown to have adenomas [2].
Clinical follow up of these individuals is a major challenge for health services.
Polyp size and number are the only reliable predictors for screened patients at risk
of future neoplastic disease, but even these are not a sensitive indicator and large
numbers of patients who will never develop a cancer are currently followed up by
colonoscopy. Dysplasia, a morphological assessment of cytological and archi-
tectural variation from normal is a better marker of progression [3], but is prone
to inter-observer variation and objective biomarkers are needed. This would
greatly assist in objective stratification of those at risk of progression to
malignancy, permitting a more targeted approach to surveillance of the increasing
number of individuals identified with colon polyps.
Disruption of cellular homeostasis is a fundamental feature of the events that
lead to carcinogenesis [4,5]. Evidence has demonstrated that carcinogenesis
proceeds in intermediate stages reflecting accumulation of mutations that drive
altered cellular behaviours, transforming normal cells to malignant derivatives
[4,5]. This is characterised by altered gene transcription controlling aspects of cell
homeostasis associated with cell proliferation, differentiation and apoptosis [4,5].
Adenomatous polyps are recognised as a potential precursor of malignant
transformation and exhibit increased proliferation of stem cells located at the base
of colon crypts. These progenitor cells generate the epithelium that lines the colon,
which becomes distorted as a consequence of hyper-proliferation, with
concomitant reduced differentiation and apoptosis [4,5]. Altered tissue micro-
architecture also becomes apparent with alteration of cellular structural
components and the associated microenvironment containing inflammatory cells
[6], fibroblasts [7] and endothelial [8] cells. Cellular processes of differentiated
cells are disrupted with altered function of endocrine cells within the epithelium
[9] and increased angiogenesis [8].
Capturing the profound changes in transcriptional regulation that occur in
adenomatous polyps and cancer presents a potential means of objectively
assessing pre-malignant changes in tissues that predispose adenomatous polyps to
malignant transformation. This has prompted interrogation of the abnormal gene
expression associated with initiation and progression of colorectal cancer using
high throughput gene expression screening technologies, such as microarray,
revealing complex altered profiles of gene expression [10,11]. It is apparent that
human colon pathology samples exhibit a broad diversity that cannot be captured
using single biomarkers. It is necessary to distil the discovery of these broad
molecular signatures into smaller gene sets of appropriate density to generate
predictive gene signature assays that have clinical utility to permit a
comprehensive insight on dysplasia and decipher information relating to cancer
initiation, staging and progression. Further problems are encountered with
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typically only very small amounts of tissue of variable quality being available for
analysis from patient biopsy samples.
These challenges are being addressed in our lab using strategies to design in-
house bespoke assays incorporating multiple gene markers to conduct gene
expression profiling using the GenomeLab System technology platform [12].
Designed multiplex assays can incorporate up to thirty gene targets and can be
conducted using very small tissue samples to generate gene signature profiles from
biopsy tissue [12]. Previous studies have demonstrated that the persistent
technical difficulties presented by multiplexed quantitative real-time PCR [13,14]
can be overcome using the GenomeLab System [12].
This report describes the development and evaluation of an in–house custom
designed cell marker multiplex, the hCellMarkerPlex, incorporating twenty-one
gene markers of key cellular processes and aspects of cell maintenance altered in
colon carcinogenesis (GeneCards http://www.genecards.org/). Archived colon
biopsy tissues collected from patients undergoing routine bowel screening were
assayed using the hCellMarkerPlex to determine distinguishing gene signature
profiles identifying normal, adenomatous polyp and carcinoma gene signatures.
The aim was to identify potential classifier genes contributing to different tissue
pathology status that can be used to apply custom designed assays that can be
applied to assist in objective prospective classification of colon pathology samples.
Materials and Methods
2.1 Biopsy specimens
Colon tissue samples (normal, adenomatous polyp and carcinoma) were obtained
from the Tayside Tissue Bank, Dundee, Scotland. The archived tissues were
obtained from patients attending for colonoscopy or surgery at Ninewells
Hospital, Dundee. All patients consented for research use of tissues using the
forms approved by Tayside Local Research Ethics Committee through the Tayside
Tissue Bank. Tissue samples were frozen and stored at 280 C˚ prior to analysis by
GeXP assay and in situ hybridisation. Formalin fixed diagnostic paraffin-
embedded tissue blocks were also stored and available for immunohistochemistry
(IHC). All tissue samples were diagnosed and graded for dysplasia using
conventional criteria within the pathology department at Ninewells Hospital,
Dundee (Table S1).
2.2 Total RNA extraction
RNA was extracted from approximately 10 mg of each colon specimen using an
RNeasy Mini Kit (Qiagen, Crawley, UK), incorporating a DNase digestion. All of
the extracted RNA samples were analysed using the Agilent Bioanalyser (Agilent
Technologies, Bracknell, UK) to obtain RIN values allowing assessment of total
RNA quality. Quantitation for downstream processing was assessed using a
Colon Pathology Gene Signatures
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Nanodrop spectrophotometer (Nanodrop Technologies). Total RNA was
aliquoted and stored at 280 C˚ prior to analysis of gene expression.
2.3 Selection of cell marker gene targets to be incorporated in the
custom designed multiplex GeXP assay, the hCellMarkerPlex
Twenty-one gene markers expressed in different colon cell types and associated
with specific cellular processes in the colon that are disrupted in response to
pathology were selected using GeneCards (http://www.genecards.org/) and were
incorporated into an in-house custom designed GeXP assay, the hCellMarkerPlex.
The hCellMarkerPlex represents 6 cell marker groups; epithelial (EZR, KRT18,
SLC9A2), proliferation (PCNA, CCND1, MS4A12), differentiation (B4GANLT2,
CDX1, CDX2), apoptotic (CASP3, NOX1 and NTN1), fibroblast (FSP1 and
COL1A1) and structural (ACTG2, CNN1 and DES) together with gene
transcription (HDAC1), stem cell (LGR5), endothelial (VWF) and mucin
production (MUC2) markers (Table S2) (see GeneCards http://www.genecards.
org/for further information on selected genes). The gene target accession numbers
were obtained from the NCBI website (http://www.ncbi.nlm.nih.gov/nuccore)
and were loaded into the Genome Lab GeXP database, together with reference
genes (UBE2D2 and B2M) and a synthetic reference control transcript (Kan(r)
supplied with the GeXP assay kit (Beckman Coulter, UK) (Table S2). B2M has
been validated as a reference marker for colon tissue in previous studies [12].
Stable expression of UBE2D2 was observed in previous gene expression analysis of
human colon tissues using the Beckman Coulter human Reference Plex (data not
published). The third reference gene is an external synthetic reference control
transcript Kan (supplied with the GeXP assay kit, Beckman Coulter, UK) used to
spike each reaction. Two reference genes were selected for normalisation as
recommended for relative quantitative gene expression analysis [15,16].
2.4 GeXP hCellMarkerplex primer assay design
The GenomeLab eXpress designer GeXP Software (Beckman Coulter, UK) was
used to identify suitable gene specific primers for reverse transcription and PCR
amplification (Table S2) as previously described [12]. Reverse PCR primers were
designed with a 39 gene specific sequence and a 59end consisting of 19 bases of
universal priming sequence. The forward PCR primers were designed with a 39
gene specific sequence and a 59end consisting of a different 18-nucleotide
universal priming sequence. The gene specific primers were designed to generate
PCR amplicons that differ in size by 4–7 base pairs, ranging in size from 137–325
(Table S2). Primer sequences were evaluated using BLAST searches to ensure
specific amplification of the designed PCR fragments. User-defined regions of the
listed sequences were selected for primer design where targets were known to be
members of a gene family to exclude homologous regions likely to cause mis-
priming and aberrant amplification. Primers with universal sequences were
purchased from Sigma-Genosys (UK).
Colon Pathology Gene Signatures
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2.5 Optimisation of the GeXP hCellMarkerPlex
The hCellMarkerPlex was optimised using total RNA extracted from normal
colon tissue. Total RNA (50 ng) was reverse transcribed using the
hCellMarkerPlex reverse primer mix and the Genome Lab GeXP start Kit
(Beckman Coulter) according to the manufacturer’s instructions. Single gene
specific reverse primers were initially diluted with nuclease-free water to a
concentration of 500 nM in each singleplex assay with each of the forward
primers (500 nM) to establish amplification of a single peak of the expected size.
A multiplex mix of forward primers was then applied, followed by attenuation of
reverse primer concentrations. Attenuation of signals beyond the linear range was
achieved by altering reverse primer concentration (in the range 15.6 nM to
1000 nM) according to manufacturer instructions. Primer concentrations used in
optimised multiplex are listed (Table S2). Reverse transcription and PCR
reactions were performed in a thermal-cycler (G Storm GS-I, GRI Ltd, UK) as
described previously [12]. No template and no reverse transcriptase controls were
conducted to ensure the absence of non-specific reaction products. GeXP PCR
reactions products were then processed as described previously [12] for capillary
electrophoresis and fragment separation using a CEQ 8800 (Beckman) as
described previously [12].
Following CEQ analysis the raw data was analysed using the Fragment Analysis
module of the GenomeLab System software (Beckman). A size exclusion filter
appropriate for the custom designed hCellMarkerPlex was applied to determine
expected size fragments. The fragment data, peak height and peak areas were then
imported to the eXpress Analysis module of the eXpress Profiler software
(Beckman) and analysed as described previously [12]. Analysis of the signal
intensity data was conducted using geNorm (http://medgen.ugent.be/genorm/) to
establish the most stably expressed transcript for normalisation purposes.
2.6 hCellMarkerPlex quantitative gene expression profiling of
colon biopsy tissues
The hCellMarkerPlex was then applied to total RNA (50 ng in triplicate) extracted
from human colon normal (n530), adenoma (n520) and carcinoma (n524)
tissues, consisting of matched normal, adenoma and carcinoma (n514), matched
normal and adenoma (n56) and matched normal and carcinoma (n510) (Table
S1). Reactions were conducted and analysed as described above. Raw data were
exported using the GenomeLab express analysis bygene export option and
normalised to each of the reference genes, UBE2D2 and B2M, incorporated in the
multiplex. The quantitative gene expression profiles generated by
hCellMarkerPlex assay were measured.
2.7 SYBR real-time PCR Assay
Complementary cDNA templates for real-time PCR assays were prepared from
Superscript II (Invitrogen) reverse transcribed total RNA (0.5 mg). SYBR real-time
Colon Pathology Gene Signatures
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PCR analysis was performed, according to the manufacturer’s instructions, using
Superarray Bioscience Corporation SYBR green master mix (Tebu-Bio, UK). Two
human MS4A12 primer pairs (Sigma-Genosys, UK) were designed to amplify
either MS4A12 variant 1 (59-gcaaaggcactaggggtgatcca-39 and 59-ggccacccca-
gaatgggtatcca-39) or MS4A12 variant 2 (59-ggcactagggtttattatctctggc-39 and
59-tcccaggctgcctttcaccag-39), together with a primer pair for the selected reference
gene UBE2D2 59-cagcacagtgttcagcaggt-39 and 59-tgaaggggtaatctgttggg-39.
All real-time PCR assays were performed using the ABI-7500Fast (Applied
Biosystems, UK). A two step cycling programme with an initial step of 10 minutes
at 95 C˚ to activate the Hotstart DNA polymerase being used, followed by 40 cycles
of 95 C˚ for 15 sec, 55 C˚ for 30 sec and 72 C˚ 30 sec was used for MS4A12 variant 1
and UBE2D2, with MS4A12 variant two being annealed at 53 C˚. The threshold
cycle number (Ct) was measured using the ABI7500Fast associated software
(Applied Biosystems). Transcript levels relative to the reference gene, UBE2D2,
were calculated (DCt). Fold expression changes between experimental groups
relative to UBE2D2 were calculated from the DDCt values.
2.8 In situ hybridisation
Frozen sections (10 mm) were cut from normal, adenomatous polyps and
carcinoma tissue (n55). In situ hybridisation was performed as described
previously [17]. The riboprobe templates for in-situ localisation were generated
by PCR using the following primer pairs: MS4A12 59-tctggtgaaaggcagcctggga-39
and 59-acagccatcattagcgaccaacc-39, SLC9A2 59-ctccccctgcaatgaagactgat-39and
59-agcaccccaccgattcccacaac-39, NOX1 59- ctgtgcccgagcgtctgc-39 and 59-
caatgccgtgaatccctaagc-39, CDX2 59- tggccggcagcgtatgg-39 and 59- tccggatggtgatg-
tagcgactgt-39 and LGR5 59- aatccccgtccaggcttttag-39 and 59- gaggcaccattcagagt-
cagt-39. The primers generated the PCR products of 484 bp MS4A12, 518 bp
NOX1, 454 bp CDX2, 464 bp SLC9A2 and 420 bp LGR5 that were cloned into
pGEM-T easy (Promega, UK) or pBluescript (Stratagene, UK) and riboprobe
template sequences were verified using a Beckman CEQ8000 Genetic Analyser.
Antisense and sense probes were synthesised from the linearised template by
in vitro transcription using RNA T7 and T3 polymerases as appropriate in the
presence of 35S-alpha-thio-UTP (NEN; 1000 Ci/mmol). Size and quality of the
35S-alpha-thio-UTP riboprobes were assessed by formaldehyde gel electrophoresis
and northern blotting prior to use. Tissue sections were hybridised with
radiolabelled riboprobes at 58 C˚ and washed to 0.16SSC at 60 C˚. Hybridised
sections were assessed initially using a Fuji phosphorimager and AIDA Image
Analyser software (Raytest Isotopenmebgerate GmBH, Germany) prior to coating
with LM-1 liquid emulsion (Amersham Pharmacia Biotech Ltd., UK) and staining
with toluidine blue. The sense riboprobe hybridised sections were examined to
assess any non-specific hybridisation.
Colon Pathology Gene Signatures
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2.9 Immunohistochemistry
Paraffin embedded tissue sections (4 mm) of normal, adenomatous polyp and
carcinoma (n58) were de-paraffinised in Histoclear (National Diagnostics) and
rehydrated through a graded alcohol series. Microwave-based antigen retrieval
was conducted using10 mM citric acid buffer (pH 6.0). Sections were
microwaved in a pressure cooker for 15 min prior to immunostaining on a
DAKO autostainer using Vectastain ABC kits (Vector Labs) according to the
manufacturer’s protocol. Sections were blocked in either normal goat or horse
serum containing 10% (v/v) stock avidin solution (Vector Labs) for 20 minutes
followed by a 1 hour incubation with CDX2 antibody (Leica Microsystems)
including 10% (v/v) from stock biotin solution (Vector Labs) to reduce
non-specific background staining. Sections were incubated with either
biotinylated anti-mouse (for monoclonal antibodies) antibody for 30 minutes
followed by VectastainH Elite ABC reagent for another 30 min. Liquid
Diaminobenzidine (DAB) (DAKO) was used as a chromogenic agent for 5
minutes and sections were counterstained with Mayer’s haematoxylin. Negative
controls were processed without addition of the primary antibody. Positive
staining was assessed morphologically by expected cellular compartment stained
(e.g. nucleus for CDX2). Intensity of staining was scored on a semi-quantitative
scale designated as follows: + 2 detectable nuclear staining, weak, ++ 2 easily
visible nuclear staining, +++ 2 strong staining and n/a – no adenoma tissue in
histological section.
2.10 Statistical analysis
Principal Component Analysis (PCA) was performed using SIMCA-P+12.0
software (MKS Instruments UK Ltd, Cheshire) on normalised and scaled data
from hCellMarkerPlex assay of the patient tissue donors to assess expression
patterns associated with normal, adenomatous polyp or carcinoma tissues. The
same software was used to perform an Orthogonal Partial Least Squares
Discriminant Analysis (OPLS-DA) [18,19]. Similar to PCA Partial Least Squares
tries to find linear combinations of variables, but conversely maximises
covariance, rather than variance, with a response variable. In PLS discriminant
analysis this response is of categorical nature (in our case the sample classes
normal, adenomatous polyp and carcinoma) and the components obtained are
chosen such that they can discriminate between the different categories. OPLS-DA
is a variation of this method in which the matrix of explanatory variables (here the
gene expression matrix) is first decomposed into a part that is orthogonal
(unpredictive) to the response and another that is predictive. This approach
improves the interpretability of the results and is widely used in metabolomics
studies [18]. Jiang et al. [20] use this technique in a similar context and detail the
OPLS-DA approach.
The Results from a linear discriminant analysis were used to assess quality of
hCellMarkerPlex gene expression profiling data from RNA templates with
different RIN values Gene expression levels were compared using a linear mixed
Colon Pathology Gene Signatures
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model in Genstat v13.2 (VSN International Ltd., Hemel Hempstead, UK)
(significance level 0.05). The analysis was conducted on a log scale if Genstat
output data identified skewed effects for a variable.
Results
3.1 Design and optimisation of the hCellMarkerPlex
Each gene specific primer pair was initially tested in a single-plex reaction. This
determined that a single peak of the expected size was generated, with no spurious
fragments produced. A multiplex primer mix of selected gene specific primers, the
hCellMarkerPlex was then prepared for multiplex gene expression analysis.
Attenuation was performed and primer concentrations giving optimal signal
detection for application of the hCellMarkerPlex to the colon biopsy tissues were
determined as listed in Table S2.
3.2 Patient biopsy specimens
The average age of patients was 65 years (range 37–82) (Table S1). Eleven patients
were female and nineteen were male. Cancers (Dukes A, B, C or C1) originated on
proximal, right side (ileum, cecum and ascending colon), hepatic flexure,
transverse and distal, left side (descending colon, sigmoid and rectum) of the gut
(Table S1). Adenomatous polyps originated from ascending colon, hepatic
flexure, sigmoid and rectum and were classified as adenoma, tubulovillous
adenoma, tubular adenoma and sessile serrated polyp (Table S1).
3.3 Gene expression profiling of cell marker genes in colon biopsy
specimens
Total RNA RIN values ranged from 2–10, indicating variations in quality (Table
S1). However, it proved possible to obtain hCellMarkerPlex gene expression
profiles from all RNA samples. Analysis of the hCellMarkerPlex gene expression
data using geNORM [21] determined that UBE2D2 exhibited the most stable
expression across the tissue samples. Subsequently all gene expression data was
normalised using UBE2D2 as a reference gene.
Linear discriminant analysis conducted on normalised hCellMarkerPlex gene
expression data provided assessment of an appropriate cut off RIN value to
exclude gene expression profiles that were adversely affected by RNA quality.
Linear discriminant analysis identified that hCellMarkerPlex assay of RNA
samples with RIN>5 did not significantly differ in discriminating tissue
pathology. Consequently, hCellMarkerPlex data derived from RNA samples with
RIN>5 were selected for further analysis.
Principal component analysis (PCA) was applied to the normalised gene
expression data obtained from total RNA samples of RIN>5 revealing that
normal, adenomatous polyp and carcinoma tissues were associated with
characteristic gene expression profiles obtained by hCellMarkerPlex assay. Two
Colon Pathology Gene Signatures
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apparent anomalous carcinoma tissue expression profiles were identified
clustering with normal biopsy expression profiles in this initial principal
component analysis. The appropriate patient samples were retrieved from the
Tayside Tissue Bank and subjected to additional pathological analysis. This
resulted in reassigning one of the patient tissue samples as normal. The second
carcinoma sample was observed to exhibit highly variant degrees of dysplasia.
Consequently, the material used for RNA extraction from this particular biopsy
may have largely consisted of tissue with a high degree of similarity to the normal
gene expression profiles obtained by hCellMarkerPlex assay. These two anomalous
samples were subsequently removed from the data set prior to further analysis.
A biplot of the PCA was constructed to further inform on associations between
gene expression profiles and biopsy type (Figure 1A). The biplot reveals specific
genes within the hCellMarkerPlex that have similar pattern of up/down regulation
in each of the different biopsy samples, normal, adenomatous polyp or carcinoma,
indicating potential classifier genes that contribute to classification of the different
pathological tissue types used in the study.
Normal tissue is characterised by higher expression levels of ACTG2, VWF,
EZR, B4GALNT2, CNN1, DES and MS4A12 and lower levels of NOX1, HDAC1,
CCND1, LGR5, PCNA, CDX1, KRT18, NTN1, CDX2 and CASP3 when compared
to adenomatous polyp or carcinoma tissues (Figure 1). Carcinoma tissue is
distinguished by significantly lower levels of SLC9A2 and increased COL1AI
compared to either normal or adenomatous polyp tissues (Figure 1A).
Statistical analysis using a mixed linear model established genes showing
significantly altered patterns of mean expression levels associated with pathology.
ACTG2, EZR, CNN1, DES, MS4A12 and NTN1 are all expressed at significantly
higher levels in normal tissue compared to adenomatous polyp or carcinoma
tissues (Figure 2). Conversely, HDAC1, CCDN1, PCNA, CDX1, KRT18, CDX2
and CASP3 are all expressed at significantly lower levels in normal tissue
compared to adenomatous polyp or carcinoma tissues (Figure 2). VWF, and
LGR5 had significant differences in mean expression levels in all three biopsy
tissues (Figure 2). NOX1 expression was significantly higher in adenomatous
polyp tissue compared to either normal or carcinoma (Figure 2). B4GALNT2,
SLC9A2 and COL1A1 were significantly altered in carcinoma compared to normal
or adenomatous polyp tissue. MUC2 expression was significantly lower in
adenomatous polyps compared to normal, but not carcinoma (Figure 1A). FSP1
and B2M did not show significantly altered expression patterns associated with
tissue pathology (Figure 2).
Both the PCA (Figure 1A) and the linear mixed model (Figure 2) results show
that tissue type is a major source of variation for the gene expression data of
hCellMarkerPlex assay, but these analyses do not tell us whether it is possible to
classify a sample as normal, adenoma or carcinoma based on the expression data
only. To answer this question OPLS-DA was used. Figure 1B shows the
corresponding bi-plot, in which component one separates the normal samples
from the rest, whereas component two distinguishes between adenoma and
carcinoma samples. The bi-plot together with the variable importance plot
Colon Pathology Gene Signatures
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Figure 1. Multivariate discriminant analysis of the UBE2D2 normalised gene GeXP hCellMarkerPlex data from human colon normal (white
triangle) (n524), adenomatous polyp (grey triangle) (n517) and carcinoma (black triangle) (n519) tissues. Information on the gene symbols on the
biplot is available in Table S2. (A) Principal component analysis (PCA) biplot permits visualisation of inherent clustering patterns of individual tissue samples
and associated gene expression levels. (B) Orthogonal Partial Least Squares Discriminant Analysis (OPLS-DA) was applied to fit a 2-class supervised
model maximising covariance and discriminating gene expression profiles associated with the different tissues sample types; the biplot shows scores and
loadings as well as the regression coefficients best explaining each class ($M4.DA(N),$M4.DA(A),$M4.DA(C). (C) Rank of importance of cell marker genes
within the OPLS-DA. (D) Matrix showing the associated misclassification rates.
doi:10.1371/journal.pone.0113071.g001
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(Figure 1C) shows that it is mainly the difference between COL1A1 and SLC9A
that discriminates between adenoma and carcinoma, whereas high values of
CCND1, PGNA, KRTA6 and LGR5 are indicative of abnormal tissues. The
associated matrix (Figure 1D) shows overall 55 out of the 58 samples were
correctly classified by this method demonstrating the potential of the
hCellMarkerPlex assay to be developed into a diagnostic tool.
3.4 Expression of long and short MS4A12 variants
The hCellMarkerPlex assay does not discriminate between the long
(NM_017716.2) and short (NM_00164470.1) variants of MS4A12. Further
validation of MS4A12 gene expression was conducted using SYBR real-time PCR
with primer assays specific for the long (NM_017716.2) and short
(NM_00164470.1) MS4A12 variants in a subset (n56) of matched normal,
adenoma and carcinoma colon patient biopsy samples. The hCellMarkerPlex
expression pattern of significant reduced expression in adenoma compared to
normal tissue and variable expression in carcinoma was validated by the SYBR
real-time PCR analysis. Both long (Figure 3A) and short (Figure 3B) MS4A12
variants show similar altered patterns of expression associated with pathology.
3.5 Localisation of selected classifier gene target expression in
normal colon, adenomatous polyp and carcinoma
Five ‘‘classifier genes’’, MS4A12, LGR5, CDX2, NOX1 and SLC9A2, contributing
to distinguishing normal, adenoma and carcinoma tissue were further validated
using in situ hybridisation to determine cellular localisation and distribution
Figure 2. Relative gene expression levels in human colon normal, adenomatous polyp and carcinoma tissue generated using the GeXP
hCellMarkerPlex assay. Gene expression is normalised to internal reference gene UBE2D2 in the hCellMarkerPlex. The letters indicate significant
(p,0.05) difference in gene expression between ‘a’ normal (n524) and either adenomatous polyp (n517) or carcinoma (n519), ‘b’ normal, adenomatous
polyp and carcinoma, ‘c’ normal and carcinoma, ‘d’ normal and adenomatous polyp and ‘e’ carcinoma and either normal of adenomatous polyp.
doi:10.1371/journal.pone.0113071.g002
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patterns of expression in normal, adenomatous polyp and carcinoma tissue
(Figure 3–7). All five genes were expressed by epithelial cells in normal,
adenomatous polyp and carcinoma. Expression levels in each tissue corroborated
patterns indicated by the gene expression measured by hCellMarkerPlex. Notably,
expression patterns were more diverse in carcinoma samples.
In normal tissues MS2A12 is expressed at high levels over the entire epithelia at
the lumenal surface with reduced expression towards lower regions of the
epithelium lining the colon crypts (Figure 3C). There is some expression apparent
at the base of the crypts, but this is very much less than at the top. In contrast
extensive epithelial expression in adenomatous polyps is absent and only a few
Figure 3. Gene expression of (A) long and (B) short form variants of MS4A12 in human colon normal, adenomatous polyp and carcinoma tissue.
Gene expression is normalised to reference gene UBE2D2. The asterisk (*) indicates significant decrease in expression levels of adenomatous polyp
compared to normal, p,0.005. (C) – (D). In situ hybridisation of MS4A12 transcripts in human colon (C) normal, (D) adenomatous polyp and (E) carcinoma.
Emulsion autoradiographs showing expression of MS4A12 at luminal epithelial surface (ep) of normal (C) in bright field and corresponding dark field images
in antisense (left) and sense (right) hybridised tissue sections (n55). MS4A12 is largely absent in adenomatous polyp (D) and localised in discrete areas of
epithelium in carcinoma (E). Bar520 mm.
doi:10.1371/journal.pone.0113071.g003
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crypts and lumenal epithelium in discrete localised areas exhibit MS4A12
expression (Figure 3D). Similarly, expression of MS4A12 is absent in most areas
of carcinoma tissue, but when visible, in areas with more regular and
differentiated epithelial structure, expression appears more intense than that seen
over adenomatous polyp tissues (Figure 3E).
In situ hybridisation confirmed the low levels of LGR5 expression in normal
tissue, with localisation observed over discrete cells within the epithelium at the
crypt base (Figure 4A). In constrast adenomatous polyps revealed extensive
expression over the epithelium (Figure 4B). LGR5 expression was also expressed
over areas of epithelium in carcinoma tissue, but expression levels were reduced in
the carcinomas compared to adenomatous polyp (Figure 4C).
CDX2 was expressed at low levels in epithelium lining the colon crypts in
normal (Figure 5A) tissue and markedly increased in adenomatous polyp
(Figure 5B) epithelium. Carcinoma tissue CDX2 expression levels were either
similar or less than those of adenomatous polyp epithelium (Figure 5C).
NOX1 was expressed at low levels in epithelium lining the colon crypts in
normal (Figure 6A) tissue, with higher levels in adenomatous polyp (Figure 6B)
epithelium. Carcinoma tissue NOX1 expression was variable with levels either
similar to those of adenomatous polyp epithelium or markedly higher
(Figure 6C).
SLC9A2 expression was difficult to visualise and necessitated long exposure of
in situ hybridised tissue sections (Figure 7). Similar patterns and level of
Figure 4. In situ hybridisation of LGR5 transcripts in human colon (A) normal, (B) adenomatous polyp
and (C) carcinoma. Emulsion autoradiographs showing expression of LGR5 in discrete single cells (arrow) in
epithelium (ep) in normal (A) and extensive expression in epithelium (ep) of adenomatous polyp (B) and
carcinoma (C) in bright field and corresponding adjacent dark field images. Antisense hybridised tissue
sections are shown to the left with sense hybridised tissue sections adjacent to the right (n55). Bar520 mm.
doi:10.1371/journal.pone.0113071.g004
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expression were observed in normal (Figure 7A) and adenomatous polyp
(Figure 7B) tissues with variable expression in carcinoma samples (Figure 7C).
3.6 CDX2 protein expression in colon normal, adenomatous polyp
and carcinoma
Immunohistochemistry revealed CDX2 protein localisation (Figure 5D - 5F)
that was consistent with in situ localisation of gene expression analysis
(Figures 5A – 5C). CDX2 protein levels were generally similar or increased in
epithelium of adenomatous polyps and carcinoma compared to normal colon
tissue (Figure 5G). Staining ranged from weak increasing to easily visible nuclear
staining (Figure 5G).
Discussion
This study demonstrates a feasible strategy to develop objective classification of
pathology status of colon biopsy tissue using bespoke assays to assess predictive
Figure 5. Localisation of CDX2 transcripts and encoded protein in human colon. In situ hybridisation of CDX2 transcripts in human colon (A) normal,
(B) adenomatous polyp and (C) carcinoma. Emulsion autoradiographs showing expression of CDX2 in epithelium (ep) in bright field and corresponding
adjacent dark field images in antisense (left) and sense (right) hybridised tissue sections (n55). Bar520 mm. (D) – (F) Representative paraffin-embedded
tissue sections show immunohistochemical localisation of CDX2 expression in the human colon epithelium in (D) normal, (E) adenomatous polyp and (F)
carcinoma. (G) Semi-quantitative scoring of staining intensity (increasing from + to +++) revealed increased immunostaining for CDX2 in adenomatous polyp
and carcinoma (n58). Scoring system: + (detectable nuclear staining, weak), ++ (easily visible nuclear staining), n/a – no adenoma tissue in histological
section.
doi:10.1371/journal.pone.0113071.g005
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gene signatures. Testing multiple markers at more than one location of
adenomatous polyp and carcinoma clinical specimens is desirable to distinguish
the variable dysplasia observed in clinical samples. GeXP assays facilitate this,
requiring only nanogram quantities of total RNA to assess multiple selected gene
targets, while remaining tissue can still be used for conventional pathological
analysis in parallel. Total RNA extracted from archived surgical biopsy tissue
samples is commonly of variable quality. However, as observed previously [12]
and in the present study, it is possible to obtain GeXP assay gene expression
profiles from total RNA extractions that have low RIN values. The ability to
measure multiple markers simultaneously within one total RNA sample generates
more comprehensive data to assess pathological status, particularly if the data for
a one marker is compromised as a consequence of sample quality, inter-individual
or within biopsy variation.
Gene expression profiling by hCellMarkerPlex assay identified potential
classifier genes that contributed markedly to classification of tissue pathology
status (Figure 1). Notably all five classifier genes selected for further analysis,
MS4A12, LGR5, CDX2, NOX1 and SLC9A2, are expressed by epithelial cells
(Figures 3–7). The aberrant expression of these gene markers is associated with
the observed profound alteration in the microarchitecture of the colon
epithelium, the origin of adenomatous polyp formation and most carcinomas in
the colon (Figures 3–7).
MS4A12 is a cell surface protein found to be predominantly expressed at the
apical surface of the colon epithelium [22]. This is supported by the localisation of
MS4A12 gene expression reported in this study (Figure 3D). It has been proposed
that MS4A12 inhibits cell proliferation and motility associated with differentiation
by regulating store operated calcium channels [22,23]. Expression has been
Figure 6. In situ hybridisation of NOX1 transcripts in human colon (A) normal, (B) adenomatous polyp
and (C) carcinoma. Emulsion autoradiographs showing expression of NOX1 in epithelium (ep) in bright field
and corresponding adjacent dark field images in antisense (left) and sense (right) hybridised tissue sections
(n55). Bar520 mm.
doi:10.1371/journal.pone.0113071.g006
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reported to be specific for colon normal and carcinoma tissues with no detectable
expression in breast, lung, prostate, gastric, renal, malignant melanoma,
hepatocellular, leukemia and head neck cancer[22]. Koslowski et al. [22] report
variable expression of the MS4A12 protein in carcinoma samples supported by the
variable localisation of gene expression in this study. It is significant to note in this
study the first report of the highly significant reduction in MS4A12 gene
expression in adenomatous polyps. This potentially reflects the greater hetero-
geneity of tissue sampled from extensive carcinomas that may contain samples
with varying degrees of dysplasia. Regions within a carcinoma may exhibit a near
normal morphology and patterns of gene expression that have a greater degree of
similarity with normal tissues.
MS4A12 is reported to be regulated by a CDX2 responsive promotor [23].
CDX2 is known to regulate gut specific genes and processes determining
differentiation of gut epithelium [24]. Notably, CDX2 was identified in this study
as a potential classifier gene with significantly elevated mean expression levels in
adenomatous polyp and carcinoma compared to normal tissue. However, while
most adenomatous polyps tested revealed elevated expression of CDX2 compared
to matched normal tissue, the carcinoma samples were more variable with some
carcinoma having comparable levels with normal tissue that are consequently
reduced compared to adenomatous polyp. Notably immunohistochemistry also
established elevated expression of CDX2 protein in adenomatous polyps
(Figure 6E, 6G). Hence, despite up-regulation of CDX2 gene and protein
expression, MS4A12 transcription, regulated by CDX2, is down-regulated in
adenomatous polyp. More detailed gene expression analysis revealed that both
transcript variants of MS4A12 are regulated in a similar pattern within tissue
Figure 7. In situ hybridisation of SLC9A2 transcripts in human colon (A) normal, (B) adenomatous
polyp and (C) carcinoma. Emulsion autoradiographs showing expression of SLC9A2 in epithelium (ep) in
bright field and corresponding adjacent dark field images in antisense (left) and sense (right) hybridised tissue
sections (n55). Bar520 mm.
doi:10.1371/journal.pone.0113071.g007
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samples. Hence, down-regulation of MS4A12 is attributed to loss of transcription
of both variants equally (Figure 3A, 3B). The results of this study support the
complex relationship between CDX2 and colon carcinogenesis reported in
previous studies [23,25,26]. Loss of CDX2 regulated gene transcription is likely to
be an important factor in the transition from ordered epithelium in normal tissue
as opposed to that of adenomatous polyps.
LGR5 is a colon stem cell marker [27] and its up-regulation is implicated in
uncontrolled proliferation of the epithelium in colon carcinogenesis associated
with b-catenin signalling [28]. It is considered to be a potential marker for colon
cancer stem cells and is linked to progression and poor prognosis in colon cancer
patients [29]. In the present study mean expression levels are significantly higher
in adenomatous polyp samples compared to either normal or carcinoma. LGR5
expression is sparse and limited to discrete single cells in the epithelial layer near
the base of colon crypts in normal tissue (Figure 4A). It is clear that the number of
LGR5 expressing cells are markedly increased and easily detected in the epithelium
of adenomatous polyps and carcinoma. In situ localisation reported here supports
the contention that LGR5 is intimately linked to either increased proliferation of
the colon stem cells or a failure to down-regulate LGR5 and initiate differentiation
(Figure 4). The significance of the higher levels of LGR5 in epithelium of
adenomatous polyps requires further investigation to determine potential links
with progression of carcinogenesis.
NOX1 is a member of the NADPH oxidase family of enzymes and generates
superoxide and H2O2. Production of the reactive oxygen species produced can
generate second messengers to suppress apoptosis [30]. Over expression of NOX1
can result in excessive generation of reactive oxygen species linked to cancer.
Activation of angiogenesis has been associated with over expression of NOX1 in
aggressive carcinomas [31].
Evidence obtained from this study indicates profound changes in epithelial
gene transcription programming during development of adenomatous polyps that
have similarities with carcinomas. Indeed aberrant gene transcription of some
markers associated with carcinogenesis, NOX1, LGR5, MS4A12, [28,31,32] reveal
greatest deviation from that of normal tissue in the adenomatous polyps prior to
development of carcinoma. Other markers, EZR and KRT18 [32,33] already
exhibit characteristics of the aberrant expression observed in carcinoma within the
adenomatous polyps. It may be inferred that transcriptional changes in
adenomatous polyps predispose them to carcinogenesis. This is characterised by
increased NOX1 and LGR5 expressing cells that indicate a proliferative phenotype
with concomitant loss of MS4A12 and EZR indicating inhibition of differentiation
and loss of epithelial cell structure. Interestingly, high COL1A1 expression, a
fibroblast marker, appears to contribute to differentiate carcinomas with
significantly lower expression of this marker in adenomatous polyps and normal
tissues.
Consequently, the identified gene signatures can provide objective classification
of diseased tissue and provide some insight on altered programming of epithelial
gene transcription that precedes or delineates carcinoma development. This study
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has established the concept of using classifier genes to develop gene signature
assays to provide objective classification of health and disease status of colon
biopsy specimens. This will facilitate further design and development of multiplex
assays that can assist pathologists to make objective decisions on disease initiation,
staging, progression and responses to treatment.
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